2020

1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

   Blood, Vol. 136, Núm. 18, pp. 2038-2050

2. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

   Journal of Clinical Oncology, Vol. 38, Núm. 28, pp. 3252-3260

3. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

   Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018